| abstract |
Polyazaheterocyclic derivatives represented by the general formula (I), pharmaceutically acceptable salts thereof, process for their preparation, and pharmaceutical compositions containing them. In the general formula, R represents hydrogen, lower alkyl, cycloalkyl, furyl, thienyl, pyridyl, or phenyl optionally having one to two substituents of halogen, lower alkyl, trifluoromethyl, alkoxy, aralkyloxy, alkylthio, aralkylthio, acyl, hydroxy, amino, nitro or cyano; R?1 represents hydrogen, cyano, carbamoyl, carboxyl, alkoxycarbonyl having optionally one to two substituents of alkoxy, cyano, -N(Ra?)(Rb?) (wherein Ra? and Rb? each represents alkyl or aralkyl or, when taken together, represent a 5 to 7-membered heterocyclic ring), nitro, phenyl or heteroaryl, or alkanoyl; R?2 represents lower alkyl, hydroxyalkyl, acetoxyalkyl, haloalkyl, dihaloalkyl, trifluoromethyl, alkoxyalkyl, dialkoxymethyl, lower alkylcarbamoyloxyalkyl, lower alkylthiocarbamoyloxyalkyl, formyl, hydroxyiminomethyl or cyano; and X, Y, and Z each represents a member of ring A and each represents N or CH. These compounds possess hypotensive, coronary vasodilating, cerebrovasodilating and cardiotonic effects, and an effect of preventing peroxidation of lipid, and are useful as agents for prevention and treatment of circulatory organ diseases. |